ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.

Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Biotechnology

ArrePath

Kurt Thorn

Deidre Johns

Paul Lukacs

Kyle Barbary

Kevin Hare

Graham H.

Erin Chinn

Science and Research Team

Board Members and Advisors

Leadership Team

ArrePath

Org chart

Teams

Science and Research Team

Board Members and Advisors

Leadership Team

Similar companies